Skip to main content

Table 1 Characteristics of patients with periprosthetic joint infections caused by methicillin-resistant Staphylococcus undergoing 2-stage revision arthroplasties

From: Methicillin-resistant Staphylococcal periprosthetic joint infections can be effectively controlled by systemic and local daptomycin

No. Sex Age Surgical procedures CCI Pathogen Antibiotic regimen (bone cement g/systemic mg/kg) Use daptomycin in bone cement at reimplantation (Y/N) FU (months) Outcome
1 M 65 DAIR for TKA 4 MRSA DAP 4/DAP 6 Y 26 Infection controlled
2 M 51 THA 4 MRSA DAP 4 + CEF 4/DAP 6 N 32 Infection controlled
3 M 72 DAIR for revision TKA 5 MRSE DAP 4/DAP 6 Y 43 Infection controlled
4 M 53 Revision THA 2 MRCoNS DAP 4 + CEF 4/DAP 6 N 42 Infection controlled
5 F 60 TKA 3 MRSA DAP 4 + CEF 4/DAP 6 Y 38 Infection controlled
6 F 80 DAIR for TKA 5 MRSE DAP 4/DAP 6 Y 26 Infection controlled
7 M 66 DAIR for THA 3 MRCoNS DAP 4/DAP 6 N 51 Infection controlled
8 M 44 DAIR for THA 2 MRSE DAP 4/DAP 6 N 42 Infection controlled
9 M 74 DAIR for TKA 4 MRSE DAP 4/DAP 6 Y 25 Infection controlled
10 M 45 DAIR for THA 3 MRSE DAP 4/DAP 6 N 26 Infection controlled
11 M 51 DAIR for THA 4 MRSA DAP 4/DAP 6 Y 44 Infection controlled
12 F 67 TKA 5 MRSA DAP 4 + CEF 4/DAP 6 Y 32 Infection controlled
13 F 86 TKA 5 MRSA DAP 4 + CEF 4/DAP 6 Y 37 Infection controlled
14 M 51 DAIR for THA 5 MRSA DAP 4/DAP 6 N 40 Infection controlled
15 F 86 TKA 5 MRSA DAP 4 + CEF 4/DAP 6 Y 30 Infection controlled
16 F 81 THA 3 MRSA DAP 4 + CEF 4/DAP 6 Y 32 Infection controlled
17 M 81 DAIR for revision TKA 5 MRSE DAP 4/DAP 6 Y 30 Infection controlled
18 M 51 DAIR for revision THA 4 MRCoNS DAP 4/DAP 6 N 31 Infection controlled
19 M 50 DAIR for THA 2 MRSE DAP 4/DAP 6 N 27 Infection controlled
20 M 87 TKA 6 MRSA DAP 4 + CEF 4/DAP 6 Y 24 Infection controlled
21 M 38 DAIR for THA 2 MRSE DAP 4/DAP 6 N 30 Infection controlled
22 M 78 DAIR for revision THA 6 MRCoNS DAP 4/DAP 6 Y 33 Infection controlled
  1. DAIR debridement, antibiotics, irrigation and prosthesis retention, CCI Charlson comorbidity index, DM diabetes mellitus, HTN hypertension, CVA cerebral vascular accident, TKA total knee arthroplasty, LC liver cirrhosis, RA rheumatoid arthritis, THA total hip arthroplasty, CAD coronary artery disease, BMI body mass index, HBV hepatic B virus, HCV hepatic C virus, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, ESRD end-stage renal disease, DAP daptomycin, CEF ceftazidime, MRSA methicillin-resistant Staphylococcus aureus, MRCoNS methicillin-resistant coagulase-negative Staphylococci, MRSE methicillin-resistant Staphylococcus epidermis, FU follow-up